<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924374</url>
  </required_header>
  <id_info>
    <org_study_id>MORELIA</org_study_id>
    <nct_id>NCT04924374</nct_id>
  </id_info>
  <brief_title>Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy</brief_title>
  <official_title>Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut microbiota can modulate the effectiveness of cancer therapies, especially&#xD;
      immunotherapy. Manipulating the microbial populations in patients with advanced lung cancer&#xD;
      through fecal microbiota transplantation from healthy individuals or from long-term survivors&#xD;
      to advanced lung cancer will enhance the efficacy of immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is a leading cause of mortality worldwide, and its treatment and prognosis are&#xD;
      being revolutionized by immunotherapy. The gut microbiome has been shown able to modulate the&#xD;
      antitumor efficacy of immunotherapeutic agents in pre-clinical models, demonstrating that&#xD;
      patients can be stratified into responders and nonresponders to immunotherapy on the basis of&#xD;
      their microbiota composition. Fecal microbiota transplants have demonstrated to improve the&#xD;
      efficacy of immunotherapy in animal models. In this study, the investigators will include 20&#xD;
      stage IV non-small cell lung cancer naïve for treatment or pretreated starting monotherapy&#xD;
      with PD/PD L-1 inhibitors in progression after a first line of chemotherapy. The participants&#xD;
      will be randomized to receive either fecal microbiota capsules from 3 donors selected based&#xD;
      on the fecal abundance of bacterial taxa shown to correlate with a greater response to&#xD;
      immunotherapy or to conventional treatment. The primary outcome will be safety. The secondary&#xD;
      outcomes will be treatment response (iRECIST criteria). The investigators will also examine&#xD;
      engraftment of donor's microbiota on host microbiota using Illumina DNA shotgun sequencing,&#xD;
      changes in the bacterial metabolism using metaproteomics, and in the plasma metabolite&#xD;
      fingerprint by untargeted mass spectrometry in bacterial and plasma samples, and changes in&#xD;
      peripheral immune cells subpopulations and antitumoral immunity. MORELIA could improve the&#xD;
      prognosis of a lung cancer in a subset of patients with limited therapeutic options and&#xD;
      inform on how to exploit host-microbiota interactions with tailored fecal microbiota&#xD;
      transplantation to boost the clinical response to immunotherapy in advanced cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of safety</measure>
    <time_frame>27 weeks</time_frame>
    <description>The safety variables (vital signs, physical examinations, symptoms, laboratory test results and the occurrence of adverse events) will be assessed at each visit. The incidence of adverse events will be categorized by severity and related to the time of occurrence. Changes in physical examinations, changes in laboratory test results (hematology, biochemistry and urinalysis tests) from screening period, and change of vital signs will be summarized and analyzed by the descriptive statistics. Adverse events will be defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Efficacy</measure>
    <time_frame>27 weeks</time_frame>
    <description>Immunotherapy Response Evaluation Criteria in Solid Tumors-iRECIST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>anti PD1 therapy plus Microbiota Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active arm: Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (&gt;30g/day).&#xD;
anti PD1 therapy every 2-3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anti PD1 therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm: no intervention before anti PD1 therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Microbiota Transplant plus anti PD1 therapy</intervention_name>
    <description>Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (&gt;30g/day).&#xD;
anti PD1 therapy every 2-3 weeks</description>
    <arm_group_label>anti PD1 therapy plus Microbiota Transplant</arm_group_label>
    <other_name>anti PD1 therapy Pembrolizumab, Nivolizumab, Atezolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti PD1 therapy</intervention_name>
    <description>anti PD1 therapy every 2-3 weeks</description>
    <arm_group_label>anti PD1 therapy</arm_group_label>
    <other_name>Pembrolizumab, Nivolizumab, Atezolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Willing to sign the informed consent&#xD;
&#xD;
               -  Age &gt;18 years.&#xD;
&#xD;
               -  Diagnosis of phase IV unresectable non-small cell cancer histologically or&#xD;
                  citologically confirmed.&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) Score ≤1&#xD;
&#xD;
               -  Disease able to be monitored using the RECIST v.1.1. criteria (lesions treated&#xD;
                  with radiotherapy can be defined as target lesions if the progression has been&#xD;
                  documented).&#xD;
&#xD;
               -  At least 3 weeks since the last treatment for cancer, including radiotherapy, and&#xD;
                  recovery ≤1 from any adverse event related with previous treatment for cancer,&#xD;
                  excluding sensorial neuropathy, anemia, asthenia, hair loss, all grade ≤2),&#xD;
                  according to the National Cancer Institute (CTCAE del NCI, v.5) definitions&#xD;
&#xD;
               -  Adequate bone marrow, renal, liver and metabolic parameters (evaluated at least 7&#xD;
                  days prior the inclusion in the study:&#xD;
&#xD;
          -  Platelet count ≥100 x 109/l, hemoglobin ≥9 g/dl and absolute neutrophil count ≥1,000 x&#xD;
             109/l.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times the upper&#xD;
             limit of normality, independently of the presence of liver metastases.&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2,5 times the upper limit of normality.&#xD;
&#xD;
          -  Total bilirubin ≤1,5 times the upper limit of normality o direct bilirubin below the&#xD;
             upper level of normality.&#xD;
&#xD;
          -  INR&lt;1,5, except if concomitant oral anticoagulation&#xD;
&#xD;
          -  Estimated glomerular filtration rate ≥30 ml/minute using the EPI equation&#xD;
&#xD;
          -  Albumin ≥3 g/dl without previous parenteral albumin treatment. • All men and women&#xD;
             with childbearing potential must accept the use of highly efficacious contraceptive&#xD;
             methods during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Combination of standard chemotherapy + immunotherapy indicated&#xD;
&#xD;
               -  Active of untreated central nervous system (CNS) involvement. Treated CNS&#xD;
                  metastases must be radiologically stable (defined as the absence of CNS&#xD;
                  progression during at least 3 weeks from the first CNS imaging after radiotherapy&#xD;
                  to the CNS imaging prior the screening visit. Participants will not be included&#xD;
                  in the presence of any neurological sign or symptom secondary to CNS metastases&#xD;
                  or radiotherapy. Any treatment with steroids must have been completed at least 14&#xD;
                  days before the first study intervention.&#xD;
&#xD;
               -  Prior use of immunotherapy of immunomodulatory treatment for non-small cell lung&#xD;
                  cancer, either in combination or in monotherapy, at any stage of the disease.&#xD;
&#xD;
               -  Radiotherapy in &gt;35% the bone marrow.&#xD;
&#xD;
               -  Prior bone marrow or cell-stem transplant.&#xD;
&#xD;
               -  Treatment with immunoestimulatory agents, including interferons or interleukin-2&#xD;
                  before 4 weeks or 5 drug half-lives (whichever longer) before the randomization.&#xD;
&#xD;
               -  Prior neoplasia, with the exception of skin basocelular carcinoma, superficial&#xD;
                  bladder carcinoma, squamous cell skin carcinoma, cervix high degree intrasquamous&#xD;
                  lesion. Those patients with prior neoplasia free of recurrence during at least 2&#xD;
                  years are eligible.&#xD;
&#xD;
               -  Severe infections four weeks before the screening, including hospitalization due&#xD;
                  to any infection, bacteremia or severe pneumonia.&#xD;
&#xD;
               -  Rectal colonization by vancomycin resistant enterococci&#xD;
&#xD;
               -  Overt immunodeficiency, including systemic treatment with steroids at &gt;10 mg of&#xD;
                  prednisone/day (or its equivalent) or other immunosuppressive agents during the&#xD;
                  14 days before the first study intervention.&#xD;
&#xD;
               -  Mucositis, GI symptoms&#xD;
&#xD;
               -  Dysphagia, history of aspirative pneumonia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sergio Serrano-Villar, MD</last_name>
    <phone>913368975</phone>
    <email>serranovillar@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pilar Garrido, MD</last_name>
    <phone>913368263</phone>
    <email>pilargarridol@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Serrano-Villar, MD, PhD</last_name>
      <email>serranovillar@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immunosenescence</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Metagenomics</keyword>
  <keyword>Metaproteomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

